logo
How often should you really be washing your bedding? A microbiologist explains

How often should you really be washing your bedding? A microbiologist explains

Yahoo07-07-2025
Most of us spend around a third of our lives in bed. Sleep isn't just downtime; it's essential for normal brain function and overall health. And while we often focus on how many hours we're getting, the quality of our sleep environment matters too. A clean, welcoming bed with crisp sheets, soft pillowcases and fresh blankets not only feels good, it also supports better rest.
But how often should we really be washing our bed linens?
According to a 2022 YouGov poll, just 28% of Brits wash their sheets once a week. A surprising number admitted to leaving it much longer, with some stretching to eight weeks or more between washes. So what's the science-backed guidance?
Let's break down what's actually happening in your bed every night – and why regular washing is more than just a question of cleanliness.
Get your news from actual experts, straight to your inbox. Sign up to our daily newsletter to receive all The Conversation UK's latest coverage of news and research, from politics and business to the arts and sciences.
Each night, as we sleep, we shed hundreds of thousands of skin cells, excrete oils from our sebaceous glands, and sweat up to half a pint of fluid – even if we've showered just before bed. Our skin hosts millions of bacteria and fungi, many of which are transferred onto sheets, pillows and duvets as we move during the night.
That fresh sweat may be odourless, but bacteria on our skin, particularly staphylococci, break it down into smelly byproducts. This is often why you wake up with body odour, even if you went to bed clean.
But it's not just about microbes. During the day, our hair and bodies collect pollutants, dust, pollen and allergens, which can also transfer to our bedding. These can trigger allergies, affect breathing, and contribute to poor air quality in the bedroom.
The flakes of skin we shed every night become food for dust mites – microscopic creatures that thrive in warm, damp bedding and mattresses. The mites themselves aren't dangerous, but their faecal droppings are potent allergens that can aggravate eczema, asthma and allergic rhinitis.
Fungi also find your bed appealing. Some species, like aspergillus fumigatus, have been detected in used bed pillows and can cause serious lung infections, particularly in people with weakened immune systems.
If you sleep with pets, the microbial party gets even livelier. Animals introduce extra hair, dander, dirt and sometimes faecal traces into your sheets and blankets, increasing the frequency at which you should be washing them.
Read more:
So, how often should you wash your bedding?
When: Weekly, or every three to four days if you've been ill, sweat heavily, or share your bed with pets.
Why: To remove sweat, oils, microbes, allergens and dead skin cells.
How: Wash at 60°C or higher with detergent to kill bacteria and dust mites. For deeper sanitisation, tumble dry or iron. To target dust mites inside pillows, freeze for at least 8 hours.
When: Vacuum at least weekly and air the mattress every few days.
Why: Sweat increases moisture levels, creating a breeding ground for mites.
Tips: Use a plastic or allergen-proof mattress protector and replace the mattress every seven years to maintain hygiene and support.
When: Every four to six months (check the label first).
Why: Internal filling can harbour bacteria and mould.
How: Wash thoroughly and dry completely to avoid fungal growth.
When: Every two weeks, or more often if pets sleep on them.
Why: They trap skin cells, sweat and allergens.
How: Wash at 60°C or as high as the care label allows. Some guidance recommends treating these like towels: regular and hot washes keep them hygienic.
When: Every three to four months, depending on usage and whether pets or children share your bed.
Why: Even with a cover, body oils and mites eventually seep into the filling.
How: Check the label: many duvets are machine-washable, others may require professional cleaning.
Your bed may look clean – but it's teeming with microbes, allergens, mites and irritants that build up fast. Washing your bedding isn't just about keeping things fresh; it's a matter of health.
Regular laundering removes the biological soup of sweat, skin, dust and microbes, which helps to reduce allergic reactions, prevent infections and keep odours at bay. And as research continues to show the profound effect of sleep on everything from heart health to mental clarity, a hygienic sleep environment is a small but powerful investment in your wellbeing.
So go ahead – strip the bed. Wash those sheets. Freeze your pillows. Your microbes (and your sinuses) will thank you.
Sweet dreams – and happy laundering.
This article is republished from The Conversation under a Creative Commons license. Read the original article.
Primrose Freestone does not work for, consult, own shares in or receive funding from any company or organisation that would benefit from this article, and has disclosed no relevant affiliations beyond their academic appointment.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Is Ultrahuman's Ring Air Now the Most Accurate Ovulation-Tracking Smart Ring?
Is Ultrahuman's Ring Air Now the Most Accurate Ovulation-Tracking Smart Ring?

CNET

time28 minutes ago

  • CNET

Is Ultrahuman's Ring Air Now the Most Accurate Ovulation-Tracking Smart Ring?

Ultrahuman's new Cycle and Ovulation Pro feature for the Ring Air has an unexpected origin story. The algorithm behind it was originally designed for intravaginal fertility monitors, but Ultrahuman has since turned it into a non-invasive, temperature-sensing tool that can track ovulation right from your finger. The wearable health tech company announced on Friday that it acquired viO HealthTech, which created the OvuSense algorithm. Validated in 13 peer-reviewed clinical publications and backed by 15 years of clinical research, the algorithm draws on data from over 260,000 cycles collected with medical-grade sensors. It was previously used in class II intravaginal medical fertility monitors. Now, Ultrahuman has adapted that technology for wellness tracking to create its Cycle and Ovulation Pro PowerPlug for the Ring Air. How accurate is Ultrahuman's Cycle and Ovulation Pro? In a press release, Ultrahuman said Cycle and Ovulation Pro delivers over 90% accuracy in confirming ovulation -- a level the company said makes the Air the "world's most accurate cycle-tracking smart ring." This data comes from equivalence testing that compared OvuSense and Ring Air with a multi-hormone ovulation prediction method that tracks rises in luteinizing hormone and progesterone. Though other cycle trackers may report different ovulation confirmation rates -- for example, the Oura Ring claims 96.4% -- that data isn't directly comparable to OvuSense and Ring Air's testing due to differences in validation protocols, datasets and definitions of detection. Ultrahuman Most platforms that track menstrual cycles rely on a 28-day cycle, but Cycle and Ovulation Pro takes into consideration that 87% of people who menstruate have varying cycles due to conditions such as polycystic ovary syndrome, endometriosis, non-bleeding, thyroid disorders or irregular bleeding. "This collaboration benefits from 15 years of clinically proven women's health expertise and applies it to the world's lightest smart ring," said Mohit Kumar, Ultrahuman CEO, in the press release. "For the first time, best-in-class hardware, software and algorithms with a clinical background come together in one wellness device. Our mission is to give women cutting-edge tools to optimize their health, combining clinical technology with comfort and style to deliver the most accurate women's health tool available." How is Pro different from the free Cycle and Ovulation PowerPlug? Cycle and Ovulation Pro complements Ultrahuman Ring Air's existing free Cycle and Ovulation PowerPlug, which provides basic conception and cycle tracking. Using physiological patterns and temperature biomarkers passively captured by the smart ring, the Pro version can support fertility planning, offer a space for mood, symptom and behavior logging and use temperature data to suggest hidden patterns in a cycle. Known as Cycle Flags, these patterns may include early, late or absent ovulation, a short luteal phase and trends potentially linked to conditions such as PCOS or miscarriage risk. Ultrahuman A note on FDA clearance While the OvuSense algorithm is FDA-cleared for intravaginal use, the adapted, non-invasive version for the Ultrahuman Ring Air was created for general wellness and isn't FDA-cleared. In other words, the Ring Air isn't a substitute for contraception or for professional medical diagnosis and treatment. For those, you should consult your health care provider. Cycle and Ovulation Pro cost Now available in the US, UK, EU, Australia and Canada, Cycle and Ovulation Pro is a premium PowerPlug in the Ultrahuman app that costs $3.99 per month or $39.99 per year. The current Cycle and Ovulation PowerPlug remains free.

Coloplast A/S - Interim Financial Report, 9M 2024/25
Coloplast A/S - Interim Financial Report, 9M 2024/25

Yahoo

time38 minutes ago

  • Yahoo

Coloplast A/S - Interim Financial Report, 9M 2024/25

2024/25 Interim financial results, 9M 2024/25 1 October 2024 - 30 June 2025 Coloplast delivered organic growth of 7% and an EBIT margin1 of 28% in Q3. Reported revenue in DKK grew 1% with negative impact from currencies and the Skin Care divestment. Organic growth rates by business area: Ostomy Care 6%, Continence Care 8%, Voice and Respiratory Care 9%, Advanced Wound Care 4% and Interventional Urology 4%. Growth in Ostomy Care was driven by broad-based contribution across regions, except for China which delivered low-single digit growth, as expected. Growth in Continence Care was driven by continued strong contribution from the Luja™ portfolio. Voice and Respiratory Care growth was driven by continued good momentum in both Laryngectomy and Tracheostomy. Growth in Advanced Wound Dressings was -2%, driven primarily by a significant decline in China which was impacted by a preventative and voluntary product return of all Biatain® Adhesive foam dressings in the market. The product return is expected to have a negative revenue impact of around DKK 80 million in H2, of which around DKK 20 million impacted Q3. Kerecis grew 17%, with a 13% EBIT margin before PPA amortisation. Growth in the quarter was impacted by a slowdown in the out-patient setting due to the LCD postponement in April, causing a temporary market shift to high-priced products. Growth momentum in Q4 is expected to improve, with a good start to the quarter in July. Growth in Interventional Urology was driven by good momentum in the US Men's Health business, partly offset by continued negative impact from the product recall in Bladder Health and Surgery of around DKK -10 million in Q3. EBIT1 was DKK 1,915 million, a 2% increase from last year. The EBIT margin1,2 was 28%, against 27% last year. Changes to the Executive Leadership Team announced, to support the successful execution of the new company strategy towards 2030. 9M 2024/25 organic growth of 7% and EBIT margin1 of 27%. Reported revenue in DKK grew 4% to DKK 20,914 million. Organic growth rates by business area: Ostomy Care 6%, Continence Care 8%, Voice and Respiratory Care 9%, Advanced Wound Care 9% and Interventional Urology 1%. EBIT1 was DKK 5,718 million, a 4% increase from last year. The EBIT margin1 was 27%, on par with last year2. Adjusted3 net profit before special items was DKK 3,778 million, a DKK 15 million decrease from last year, negatively impacted by non-cash effect from net financial expenses. Adjusted3 diluted earnings per share (EPS) before special items decreased by 1% to DKK 16.76. Adjusted3 ROIC after tax before special items was 15%, on par with last year. FY 2024/25 guidance is unchanged with organic growth of around 7% and an EBIT margin before special items of 27-28%. Organic growth now includes the negative impact from the product return in Advanced Wound Dressings in China, partly offset by good momentum in the other business areas. Reported growth in DKK is now expected to be 3-4%, with around 2%-points negative impact from currencies and around 1.5%-points negative impact from the Skin Care divestment. The assumptions on the reported EBIT margin before special items are largely unchanged. Special items expectations are unchanged, around DKK 450 million. Expectations on capital expenditures and tax rate (ordinary and effective) are also unchanged. "We deliver a third quarter as expected with 7% organic growth and an EBIT margin of 28%, maintaining our financial guidance for 2024/25. Our Q3 performance was driven by broad-based growth across our chronic care businesses, offsetting the challenges in China. I'm pleased to see the global Coloplast organisation continuing to deliver on our priorities and moving the business forward. The search for Coloplast's new CEO remains on track. I look forward to presenting our 2030 strategy at our Capital Markets Day on 2 September alongside the new Executive Leadership Team, announced today,' says interim CEO Lars Rasmussen. 1. before special items expenses of DKK 83 million in Q3 2024/25 and DKK 241 million in 9M 2024/25. 2. before special items expenses of DKK 36 million in Q3 2023/24 and DKK 70 million in 9M 2023/24. 3. Adjusted for the impact from the Kerecis IP transfer. Conference call Coloplast will host a conference call on Tuesday, 19 August 2025 at 11.00 CEST. The call is expected to last about one actively participate in the Q&A session please sign up ahead of the conference call on the link here to receive an e-mail with dial-in details: Register hereAccess the conference call webcast directly here: Coloplast - 9M 2024/25 conference call For further information, please contact Investors and analystsAnders Lonning-SkovgaardExecutive Vice President, CFOTel. +45 4911 1111 Aleksandra DimovskaVice President, Investor RelationsTel. +45 4911 1800 / +45 4911 2458Email: dkadim@ Kristine Husted MunkSenior Manager, Investor RelationsTel. +45 4911 1800 / +45 4911 3266Email: dkkhu@ Simone Dyrby HelvindSenior Manager, Investor RelationsTel. +45 4911 1800 / +45 4911 2981Email: dksdk@ Press and mediaPeter MønsterSr. Media Relations ManagerTel. +45 4911 2623Email: dkpete@ AddressColoplast A/SHoltedam 1DK-3050 HumlebaekDenmarkCompany reg. (CVR) no. 69749917 This announcement is available in a Danish and an English-language version. In the event of discrepancies, the English version shall prevail. Coloplast was founded on passion, ambition, and commitment. We were born from a nurse's wish to help her sister and the skills of an engineer. Guided by empathy, our mission is to make life easier for people with intimate healthcare needs. Over decades, we have helped millions of people to live a more independent life and we continue to do so through innovative products and services. Globally, our business areas include Ostomy Care, Continence Care, Advanced Wound Care, Interventional Urology and Voice and Respiratory Care. The Coloplast logo is a registered trademark of Coloplast A/S. © rights reserved Coloplast A/S, 3050 Humlebaek, Denmark. Attachment 06_2025_9M_2024_25_Earnings_releaseError in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

argenx to Host R&D Webinar Highlighting ARGX-119 on September 16, 2025
argenx to Host R&D Webinar Highlighting ARGX-119 on September 16, 2025

Yahoo

timean hour ago

  • Yahoo

argenx to Host R&D Webinar Highlighting ARGX-119 on September 16, 2025

August 19, 2025Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced it will host a webinar, titled 'R&D Spotlight | Pioneering MuSK Biology with ARGX-119' on Tuesday, September 16, 2025, at 2:00pm ET. The webinar will be the first of a 'mini' series highlighting the argenx pipeline and research and development strategy. argenx management and scientific leadership will be joined by key opinion leaders, who will discuss the development of the MuSK agonist program, ARGX-119, and its potential to treat neuromuscular diseases, including congenital myasthenic syndromes (CMS), amyotrophic lateral sclerosis (ALS) and spinal muscular atrophy (SMA). A webcast of the event can be accessed on the Investors section of the argenx website at A replay of the webcast will be available on the argenx website for approximately one year following the presentation. About argenx argenx is a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases. Partnering with leading academic researchers through its Immunology Innovation Program (IIP), argenx aims to translate immunology breakthroughs into a world-class portfolio of novel antibody-based medicines. argenx developed and is commercializing the first approved neonatal Fc receptor (FcRn) blocker and is evaluating its broad potential in multiple serious autoimmune diseases while advancing several earlier stage experimental medicines within its therapeutic franchises. For more information, visit and follow us on LinkedIn, Instagram, Facebook, and YouTube. Contacts Media: Colin McBeancmcbean@ Investors: Alexandra Royaroy@

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store